A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Cancer Cell

• Publication date

  2010-04-13

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ccr.2009.12.050PMID 20385364PMCID PMC2858395
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Protein data bank

  2012cited by this paper
• Molecular docking and ligand specificity in fragment-based inhibitor discovery.

  2009cited by this paper
• A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo.

  2009influential reference
• Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines.

  2009cited by this paper
• CtBP Is an Essential Corepressor for BCL6 Autoregulation

  2008cited by this paper
• BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells.

  2008cited by this paper
• Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer.

  2008influential reference
• Sequential transcription factor targeting for diffuse large B-cell lymphomas.

  2008influential reference
• BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms.

  2007cited by this paper
• Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR

  2007influential reference
• Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G.

  2007cited by this paper
• Phaser crystallographic software

  2007cited by this paper
• Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

  2007influential reference
• Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas

  2007influential reference
• Computational identification of inhibitors of protein-protein interactions.

  2007cited by this paper
• Crystal structure of the BTB domain from the LRF/ZBTB7 transcriptional regulator

  2006cited by this paper
• HKL-3000: the integration of data reduction and structure solution--from diffraction images to an initial model in minutes.

  2006cited by this paper
• Improving the Design and Analysis of High-Throughput Screening Technology Comparison Experiments Using Statistical Modeling

  2006influential reference
• BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells

  2005cited by this paper
• Identification of novel extracellular signal-regulated kinase docking domain inhibitors.

  2005cited by this paper
• Deregulated BCL6 expression recapitulates the pathogenesis of human diffuse large B cell lymphomas in mice.

  2005cited by this paper
• Reprogramming Specific Gene Expression Pathways in B-Cell Lymphomas

  2005cited by this paper
• Combined PET and microdialysis for in vivo assessment of intracellular drug pharmacokinetics in humans.

  2005cited by this paper
• Sequence and structural analysis of BTB domain proteins

  2005cited by this paper
• Anatomy of Fingerprint Search Calculations on Structurally Diverse Sets of Active Compounds

  2005cited by this paper
• The human BCL6 transgene promotes the development of lymphomas in the mouse.

  2004cited by this paper
• Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells

  2004influential reference
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells

  2004cited by this paper
• Identification of non-phosphate-containing small molecular weight inhibitors of the tyrosine kinase p56 Lck SH2 domain via in silico screening against the pY + 3 binding site.

  2004cited by this paper
• Identification and characterization of small molecule inhibitors of the calcium-dependent S100B-p53 tumor suppressor interaction.

  2004cited by this paper
• MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation.

  2004cited by this paper
• Emerging classes of protein-protein interaction inhibitors and new tools for their development.

  2004cited by this paper
• Consideration of Molecular Weight during Compound Selection in Virtual Target-Based Database Screening

  2003cited by this paper
• Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain.

  2003influential reference
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.

  2002influential reference
• Macromolecular therapeutics: emerging strategies for drug discovery in the postgenome era.

  2001cited by this paper
• DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases

  2001influential reference
• Computational model of intracellular pharmacokinetics of paclitaxel.

  2000cited by this paper
• BCL-6 in the Pathogenesis of Non-Hodgkin's Lymphoma

  2000cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000influential reference
• Unsupervised Data Base Clustering Based on Daylight's Fingerprint and Tanimoto Similarity: A Fast and Automated Way To Cluster Small and Large Data Sets

  1999cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• All-atom empirical potential for molecular modeling and dynamics studies of proteins.

  1998cited by this paper
• Refinement of macromolecular structures by the maximum-likelihood method.

  1997cited by this paper
• Control of inflammation, cytokine expression, and germinal center formation by BCL-6.

  1997cited by this paper
• The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation

  1997cited by this paper
• Azithromycin pharmacokinetics and intracellular concentrations in Legionella pneumophila-infected and uninfected guinea pigs and their alveolar macrophages

  1994cited by this paper
• Uptake of azithromycin by human monocytes and enhanced intracellular antibacterial activity against Staphylococcus aureus

  1993cited by this paper
• Structure-Based Strategies for Drug Design and Discovery

  1992influential reference
• CHARMM: A program for macromolecular energy, minimization, and dynamics calculations

  1983cited by this paper
• A geometric approach to macromolecule-ligand interactions.

  1982influential reference

• Discovery of pyrrolopyrimidinone inhibitors of the BCL6-SMRT corepressor interaction.

  2026cites this paper
• Resveratrol as a BCL6 natural inhibitor suppresses germinal center derived Non-Hodgkin lymphoma cells growth

  2025cites this paper
• Small molecule BCL6-inhibition suppresses follicular T helper cell differentiation and plasma blast formation.

  2025cites this paper
• BCL6 inhibition: a promising approach to prevent germinal center-driven allo-immune responses

  2025cites this paper
• B-cell lymphoma 6 in breast cancer: molecular mechanisms and clinical significance

  2025cites this paper
• Selectively targeting BCL6 using a small-molecule inhibitor is a potential therapeutic strategy for glioblastoma

  2025cites this paper
• Dietary lipids induce PPARd and BCL6 to repress macrophage IL-23 induction after intestinal injury and LPS exposure

  2025cites this paper
• Dietary lipids induce PPARd and BCL6 to repress macrophage IL-23 induction after intestinal injury and LPS exposure

  2025cites this paper
• Structure-based discovery of sulfamoyl-ethyl-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidine amides and sulfonamides as potent B-Cell Lymphoma 6 (BCL6)-BTB inhibitors.

  2025cites this paper
• Kaiso mediates transcription and RNA splicing in colorectal carcinoma: role of BRCA1 in the Kaiso enhanceosome

  2025cites this paper
• BCL6, DUSP3, and IL6R Are Identified as Shared Druggable Immune-Regulatory Axis in Atrial Fibrillation and Atherosclerosis Through Integrative In Silico and In Vitro Analysis

  2025cites this paper
• Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma.

  2025cites this paper
• The ZBTB family in cardiac development and diseases.

  2025cites this paper
• Specific radiation damage to halogenated inhibitors and ligands in protein–ligand crystal structures

  2024cites this paper
• BCL6 confers resistance to HDAC inhibitors in DLBCL.

  2024cites this paper
• Zinc Finger and BTB Domain-Containing 20: A Newly Emerging Player in Pathogenesis and Development of Human Cancers

  2024cites this paper
• Selective deletion of E3 ubiquitin ligase FBW7 in VE-cadherin-positive cells instigates diffuse large B-cell lymphoma in mice in vivo

  2024cites this paper
• Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer

  2024cites this paper
• How CBX proteins regulate normal and leukemic blood cells

  2024cites this paper
• A small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth.

  2024cites this paper
• Current perspectives and trend of computer-aided drug design: a review and bibliometric analysis

  2024cites this paper
• Chalcones: Potential Chemotherapeutic Compounds and Educational Tools for Closing the Loop in STEM.

  2023cites this paper
• Reactive fragments targeting carboxylate residues employing direct to biology, high-throughput chemistry

  2023cites this paper
• Targeting Bcl-6 prevents sclerodermatous chronic graft-versus-host disease by abrogating T follicular helper differentiation in mice.

  2023cites this paper
• Discovery of OICR12694: A Novel, Potent, Selective, and Orally Bioavailable BCL6 BTB Inhibitor.

  2023cites this paper
• Facilitating the development of molecular glues: Opportunities from serendipity and rational design.

  2023cites this paper
• Evaluation of Rhodanine Indolinones as AANAT Inhibitors

  2023cites this paper
• Mouse models of diffuse large B cell lymphoma

  2023cites this paper
• BTB domains: A structural view of evolution, multimerization, and protein–protein interactions

  2022cites this paper
• Impact of SNPs, off-targets, and passive permeability on efficacy of BCL6 degrading drugs assigned by virtual screening and 3D-QSAR approach

  2022cites this paper
• Full Title: The DNA binding protein BCL6 regulates NFκB-controlled endothelial inflammatory gene expression Short Title: BCL6 modifies endothelial inflammation Authors:

  2022influential citation
• Balance between immunoregulatory B cells and plasma cells drives pancreatic tumor immunity

  2022cites this paper
• B-cell Lymphoma 6 Inhibitors: Current Advances and Prospects of Drug Development for Diffuse Large B-cell Lymphomas.

  2022cites this paper
• Increased slow dynamics defines ligandability of BTB domains

  2022cites this paper
• The Central Role of the Ubiquitin–Proteasome System in EBV-Mediated Oncogenesis

  2022cites this paper
• TBL1X: AT THE CROSSROADS OF TRANSCRIPTIONAL AND POST-TRANSCRIPTIONAL REGULATION.

  2022cites this paper
• B-cell Lymphoma 6 (BCL6): From Master Regulator of Humoral Immunity to Oncogenic Driver in Pediatric Cancers

  2022cites this paper
• Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective

  2022cites this paper
• Discovering cell-active BCL6 inhibitors: effectively combining biochemical HTS with multiple biophysical techniques, X-ray crystallography and cell-based assays

  2022cites this paper
• Emerging mechanisms of targeted protein degradation by molecular glues.

  2022cites this paper
• Into Deep Water: Optimizing BCL6 Inhibitors by Growing into a Solvated Pocket

  2021cites this paper
• Structural basis of Apt48 inhibition of the BCL6 BTB domain.

  2021cites this paper
• Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond.

  2021cites this paper
• Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy

  2021cites this paper
• An orally available small molecule BCL6 inhibitor effectively suppresses diffuse large B cell lymphoma cells growth in vitro and in vivo.

  2021cites this paper
• Recent Developments in Oxazole Derivatives as Anticancer Agents: Review on Synthetic Strategies, Mechanism of Action and SAR studies.

  2021cites this paper
• GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice

  2021influential citation
• Gluing Proteins for Targeted Degradation.

  2021cites this paper
• An in vivo genome‐wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer

  2021cites this paper
• An Overview on Diffuse Large B-Cell Lymphoma Models: Towards a Functional Genomics Approach

  2021cites this paper
• Identification of an atypical interaction site in the BTB domain of the MYC-interacting zinc-finger protein 1.

  2021cites this paper
• ZBTB Transcription Factors: Key Regulators of the Development, Differentiation and Effector Function of T Cells

  2021cites this paper
• Rationally Designed Covalent BCL6 Inhibitor That Targets a Tyrosine Residue in the Homodimer Interface.

  2020cites this paper
• The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy

  2020cites this paper
• Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice

  2020cites this paper
• Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders

  2020cites this paper
• Targeting epigenetic protein-protein interactions with small-molecule inhibitors.

  2020cites this paper
• Structural analysis of the PATZ1 BTB domain homodimer

  2020cites this paper
• Bcl-6-directed follicular helper T cells promote vascular inflammatory injury in diabetic retinopathy

  2020cites this paper
• GITR Agonism Triggers Antitumor Immune Responses through IL21-Expressing Follicular Helper T Cells

  2020influential citation
• Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis

  2020cites this paper
• Immediate Adaptation Analysis Implicates BCL6 as an EGFR-TKI Combination Therapy Target in NSCLC

  2020cites this paper
• Prognostic signficance of tumor cell markers in diffuse large B-cell lymphoma with special emphasis on lymphoma localization

  2020cites this paper
• TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate.

  2020cites this paper
• Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth.

  2020cites this paper
• Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level

  2020cites this paper
• AID assists DNMT1 to attenuate BCL6 expression through DNA methylation in diffuse large B-cell lymphoma cell lines

  2020cites this paper
• Triterpenoids Extracted from Rhus chinensis Mill Act Against Colorectal Cancer by Inhibiting Enzymes in Glycolysis and Glutaminolysis: Network Analysis and Experimental Validation

  2020cites this paper
• Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine

  2020cites this paper
• Small molecule-induced polymerization triggers degradation of BCL6

  2020cites this paper
• SAMPL7: Host–guest binding prediction by molecular dynamics and quantum mechanics

  2020cites this paper
• Characterizing therapeutic signatures of transcription factors in cancer by incorporating profiles in compound treated cells

  2020cites this paper
• The Function of Oncogene B-Cell Lymphoma 6 in the Regulation of the Migration and Invasion of Trophoblastic Cells

  2020cites this paper
• B cells in chronic graft-versus-host disease.

  2019cites this paper
• A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

  2019cites this paper
• Epigenetic Programing of B-Cell Lymphoma by BCL6 and Its Genetic Deregulation

  2019cites this paper
• Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications

  2019cites this paper
• Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 (BCL6) BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design

  2019cites this paper
• BCL6 inhibitor FX1 attenuates inflammatory responses in murine sepsis through strengthening BCL6 binding affinity to downstream target gene promoters.

  2019cites this paper
• Long non‐coding RNA SNHG16 promotes proliferation and inhibits apoptosis of diffuse large B‐cell lymphoma cells by targeting miR‐497‐5p/PIM1 axis

  2019cites this paper
• Molecular pathogenesis of germinal center‐derived B cell lymphomas

  2019cites this paper
• Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML

  2019cites this paper
• Phenotypic Characterization of Diffuse Large B-Cell Lymphoma Cells and Prognostic Impact

  2019cites this paper
• Histone deacetylase 3 controls a transcriptional network required for B cell maturation

  2019influential citation
• Omics Studies in Hemoglobinopathies

  2019cites this paper
• Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells

  2019cites this paper
• Germinal center‐derived lymphomas: The darkest side of humoral immunity

  2019cites this paper
• Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma

  2019cites this paper
• Microfluidic assembly of hydrogel‐based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release

  2019cites this paper
• Deletion of the Miz-1 POZ domain increases efficacy of cytarabine treatment in T- and B-ALL/lymphoma mouse models.

  2019cites this paper
• Current perspectives on the treatment of double hit lymphoma

  2019cites this paper
• Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies

  2019cites this paper
• Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease.

  2019cites this paper
• Protein-protein interaction modulators: advances, successes and remaining challenges

  2019cites this paper
• Burkitt Lymphoma and Diffuse Large B-Cell Lymphoma

  2019cites this paper
• Genetics of diffuse large B-cell lymphoma.

  2018cites this paper
• Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.

  2018cites this paper
• THE SURVIVAL IMPACT OF COMBINED EXPRESSION OF MYC, BCL2 AND BCL6 IN DIFFUSE LARGE B CELL LYMPHOMA PATIENTS

  2018cites this paper
• BCL6 as a therapeutic target for lymphoma

  2018cites this paper
• Pathology and Molecular Pathogenesis of DLBCL and Related Entities

  2018cites this paper